Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using theemail support widget if the problem persists.
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various th...
Data could not be retrieved
| 524494 | Peers | Sector | |
|---|---|---|---|
Market Cap | 363.6 B | 624 B | 5.606 B |
Price % of 52 Week High | Premium | 82.8% | 62.3% |
Dividend Yield | 0.3% | 0.9% | 0.0% |
Shareholder Yield | Premium | 1.1% | -0.7% |
1 Year Price Total Return | 20.8% | 9.4% | -11.0% |
Beta (5 Year) | 0.30 | 0.41 | 0.64 |
No data available
| 10Y DCF EBITDA ExitView Updated 7 hours ago |
| 10Y DCF Revenue ExitView Updated 7 hours ago |
| 10Y DCF Growth ExitView Updated 7 hours ago |
| 5Y DCF EBITDA ExitView Updated 7 hours ago |
| 5Y DCF Revenue ExitView Updated 7 hours ago |
| 5Y DCF Growth ExitView Updated 7 hours ago |
| DDM Multi StageView Updated 7 hours ago |
| DDM Stable GrowthView Updated 7 hours ago |
| DuPont ROE AnalysisView Updated 3 days ago |
| EV / EBIT MultiplesView Updated 7 hours ago |
| EV / EBITDA MultiplesView Updated 7 hours ago |
| P/E MultiplesView Updated 7 hours ago |
| Price / Book MultiplesView Updated 7 hours ago |
| Price / Sales MultiplesView Updated 7 hours ago |
| EV / Revenue MultiplesView Updated 7 hours ago |
| CAPM WACC ModelView Updated 17 hours ago |
| Earnings Power ValueView Updated 7 hours ago |
| 10Y Historical FinancialsView Updated 3 days ago |
| 5Y Historical FinancialsView Updated 3 days ago |
| (INR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 62,481 | 77,059 | 87,268 | 20,529 | 22,454 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 14,813 | 14,384 | 12,022 | 19,875 | 12,022 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | 3,113 | 5,341 | 8,977 | 0.00 | - |